This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
269,00 € per year
only 22,42 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Clore, J. & Scott, P. J. H. [68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Expert Rev. Mol. Diagn. 24, 565–582 (2024).
Rodnick, M. E. et al. Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nat. Protoc. 17, 980–1003 (2022).
Makarem, A., Han, J. & Klika, K. D. Byproducts in the synthesis of [68Ga]Ga-PSMA-11. Nat. Protoc. https://doi.org/10.1038/s41596-025-01164-6 (2025).
Eder, M. et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 23, 688–697 (2012).
Afshar-Oromieh, A. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 40, 486–495 (2013).
Carlucci, G. et al. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J. Nucl. Med. 62, 149–155 (2021).
Wang, I. E. et al. A comparison of routine [68Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits. EJNMMI Radiopharm. Chem. 9, 87 (2024).
Eder, M. et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 7, 779–796 (2014).
Vogg, A. et al. 68Ga-PSMA-11 prepared with the Telix kit versus a traditional synthesiser: does it matter? J. Nucl. Med. 62, 1463 (2021).
Assadi, M. & Dadgar, H. Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer. World J. Nucl. Med. 19, 93–98 (2019).
Abghari-Gerst, M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multi-center study in 2005 patients. J. Nucl. Med. 63, 567–572 (2022).
Martin, S. et al. Identification, characterization, and suppression of side products formed during the synthesis of [177Lu]Lu-PSMA-617. J. Med. Chem. 64, 4960–4971 (2021).
Ioppolo, J. A., Alvarez de Eulate, E., Cullen, D. R., Mohamed, S. & Morandeau, L. Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [18F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer. J. Label Compd. Radiopharm. 66, 58–72 (2023).
Cardinale, J. et al. Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals 10, 77 (2017).
Wang, Y. et al. Preparation of 68Ga-PSMA-11 with a synthesis module for micro PET-CT imaging of PSMA expression during prostate cancer progression. Contrast Media Mol. Imaging 2018, 8046541 (2018).
Migliari, S. et al. Development and validation of a high-pressure liquid chromatography method for the determination of chemical purity and radiochemical purity of a [68Ga]-labeled Glu–urea–Lys(Ahx)-HBED-CC (positron emission tomography) tracer. ACS Omega 2, 7120–7126 (2017).
Fuscaldi, L. L. et al. Standardization of the [68Ga]Ga-PSMA-11 radiolabeling protocol in an automatic synthesis module: assessments for PET imaging of prostate cancer. Pharmaceuticals 14, 385 (2021).
Acknowledgements
We thank A. Afshar-Oromieh, K. Kopka (now at HZDR) and their colleagues at the University Hospital of Heidelberg and the German Cancer Center (DKFZ) Heidelberg for the valuable assistance in qualifying UM for clinical production of [68Ga]Ga-PSMA-11 for the original protocol. P.J.H.S. thanks the University of Michigan Department of Radiology for financial support, as well as M. E. Rodnick for implementing the [68Ga]Ga-PSMA-11 syntheses used at UM and described in the original protocol.
Author information
Authors and Affiliations
Contributions
K.G. and P.J.H.S. conceived and developed the original project and provided supervision and funding. D.S. and A.K. conducted radiosyntheses and QC at RPA. S.E. assisted with project development and target and cyclotron aspects at RPA. M.J.F. is a PET physician, provided funding for the RPA contribution and contributed to the manuscript. All authors contributed to this reply.
Corresponding authors
Ethics declarations
Competing interests
K.G. is an employee of GE HealthCare. The other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Katsifis, A., Stark, D., Fulham, M.J. et al. Reply to: Byproducts in the synthesis of [68Ga]Ga-PSMA-11. Nat Protoc (2025). https://doi.org/10.1038/s41596-025-01163-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41596-025-01163-7
